NASH market Report The nonalcoholic steatohepatitis market is poised for significant expansion with the approval of REZDIFFRA and a robust clinical development pipeline. Key companies shaping the future of NASH treatment include Inventiva Pharma, Zydus Therapeutics, Novo Nordisk, Eli Lilly and Company, Madrigal Pharmaceuticals, Terns, Inc., Intercept Pharmaceuticals, Enyo Pharma, 89bio, Inc., Akero Therapeutics, Inc., […]
